Dr. Jason Zielonka retired from Eli Lilly & Company at the end of December 2017, completing a 30-year career in the pharmaceutical industry and entering the next phase of his career, as a mentor, consultant, world traveler and grandfather.
Dr. Zielonka has held positions with several biopharmaceutical and consulting organizations, including Bristol-Myers Squibb, Novo Nordisk, Sterling Winthrop, Dupont Pharma, Pfizer (in the UK and US), and Johnson & Johnson. He was also a full-time consultant to FDA, helping implement and manage the current Adverse Event Reporting System (AERS) and serving as its first head of clinical coding and evaluation. The roles he has held have included global patient safety, clinical research, medical affairs, and exploratory medicine. During this period, he led or participated in six successful first-in-class product development teams.
Prior to his corporate career, Dr. Zielonka was an academic physician, holding the positions of Instructor in Radiology at the Harvard Medical School (and the Massachusetts General Hospital) and Assistant Professor of Radiology at the Medical College of Wisconsin (and Chief of the Nuclear Medicine Service at the Milwaukee VA Medical Center). He also served as a consultant to numerous imaging and radiopharmaceutical companies during that period, including GE Medical Systems and Siemens.
His education includes degrees from MIT (BS, Electrical Science & Engineering) and Yale University (MD) as well as post-graduate residency & fellowship in Nuclear Medicine at the Harvard Medical School.